Kornimate/medical-research-clean huggingface dataset:
japanese coronary intervention using drug eluting and perfusion therapy for left main disease (jdepth-lm registry)

Conditions: Stable Angina; Non-ST-elevation Acute Coronary Syndrome; Unstable Angina

Summary: jdepth-lm registry is a prospective, observational, multi-center study designed for the efficacy and safety of double-effect kissing balloon technique (w-kbt) in left main (lm) bifurcation percutaneous coronary intervention (pci) using perfusion balloon (pb) and drug coated balloon (dcb) in patients with left main coronary artery disease (lmd) with left circumflex artery (lcx) ostium stenosis.

jdepth-lm registry is a prospective observational multi-center study. the investigators will enroll and treat patients in the registry who meet the selection criteria under usual care and for whom pci with w-kbt following on crossover stenting for lmt-lad direction, proximal optimization technique (pot), and conventional kissing balloon technique (c-kbt) is the optimal treatment. the operators shall obtain oral or written consent from patients who meet the criteria before performing pci, indicating the intention to perform pci with w-kbt, and shall keep records. the investigators will continuously register cases attempting pci with w-kbt according to the protocol and evaluate its efficacy and safety using data from this multi-center registry.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years 2. patient with stable coronary artery disease, non-st-elevation myocardial infarction, or unstable angina 3. left main disease confirmed by coronary angiography or coronary ct angiography 4. clinical and anatomical eligibility for pci as agreed by the local heart team 5. patient with consent prior to undergoing pci 6. left main medina classification (1,1,1), (1,0,1), (0,1,1), (0,0,1) confirmed by coronary angiography 7. de novo target lesion in lmt-lad amenable for crossover stenting with provisional side-branch approach as determined by pci operator 8. de novo ostial lcx lesions 9. lesion indicated in no. 8 with a length of less than 10 mm or a stenosis of less than 70% confirmed by coronary angiography exclusion criteria: 1. inability to provide written informed consent 2. patient with a history of st-elevation myocardial infarction within the previous 1 week 3. patient in a state of cardiogenic shock 4. patient with a history of coronary artery bypass grafting 5. patient with malignant tumors or other conditions with a life expectancy of less than one year 6. patient considered suitable for stent placement in the ostial lcx from a medical perspective 7. patient considered unsuitable for anti-thrombotic therapy after pci 8. other patient whom the investigator deems unsuitable for the safe conduct of lm-pci, including w-kbt

Keywords: ischemic heart disease
preventive effect of pitavastatin on contrast-induced nephropathy in patients with renal dysfunction

Conditions: Contrast-induced Nephropathy

Summary: contrast-induced nephropathy (cin) is a well-recognized complication of radiographic contrast administration and is associated with increased short- and long-term mortality. previous strategies including forced diuresis with diuretics or mannitol, intravenous administration of fenoldopam or dobutamine, and postprocedure hemodialysis to prevent cin have been largely unsuccessful. in addition, the use of n-acetylcysteine to prevent cin has yielded conflicting outcomes. a review of a large insurance database and retrospective study have shown that statins therapy is associated with a lower incidence of cin after percutaneous coronary intervention. the preventive effect of statins on cin may be attributed to direct pleiotropic effects on the vascular wall such as improvement of endothelial dysfunction, anti-inflammatory or anti-oxidative effect. however, recent randomized trial could not demonstrate the preventive effect of statin on cin in patients with chronic kidney disease. thus, we will investigate the preventive effect of pitavastatin on cin in patient with renal dysfunction undergoing coronary angiography or intervention.


Eligibility criteria:
inclusion criteria: * age ≥ 19 years * need for coronary angiography or intervention in patients with typical symptoms for angina or myocardial infarction, or documented myocardial ischemia at non-invasive studies including ecg, treadmill ecg test, heart spect or coronary ct angiography * estimated glomerular filtration rate ≤60 ml/min * informed consent exclusion criteria: * need for primary percutaneous coronary intervention or emergent intervention in patients with myocardial infarction * allergic reaction for contrast agent (visipaque) or statin * contraindication for contrast agent (visipaque) or statin * shock status fron any cause including cardiogenic shock * statin use before enrollment (enrollment after 2 weeks of wash-out period) * exposure of contrast agent within 7 days before enrollment * pregnancy or expectation for pregnancy in women of childbearing age * heart failure (nyha class ≥3 or left ventricular ejection fraction \< 40%) * acute renal injury * dialysis therapy * mechanical ventilator * life expectancy \< 6 months * non-steroidal anti-inflammatory drug, dopamine, mannitol or n-acetylcysteine, ascorbic acid within 48 hours before and after coronary angiography/intervention * severe hepatic dysfunction * eisenmenger syndrome or idiopathic pulmonary hypertension * renal artery angioplasty within 6 months * single functioning kidney * kidney transplantation

Keywords: contrast-induced nephropathy prevention statin pitavastatin
neurocognitive function changes with extended-release tacrolimus among older kidney transplant recipients

Conditions: Kidney Transplant Recipients; Old Age

Summary: the objective of this randomized controlled study is to assess the neurocognitive outcomes between individuals using immediate-release (ir) tacrolimus (prograf®) and those who were converted to extended-release tacrolimus (envarsus xr) among older kidney transplant recipients (ktrs).


Eligibility criteria:
inclusion criteria: * able to give informed consent for participation in the study * patients who have regular outpatient follow-up at the massachusetts general hospital (mgh) transplant center * ≥1 year since the latest kidney transplantation * on ir tacrolimus as maintenance therapy * at a stable therapeutic tacrolimus level (5-10 ng/ml) over the last ≥3 months * stable kidney function \[\<20% variability between the last two estimated glomerular filtration rate (egfr)\] * utilizing english or spanish as the primary language exclusion criteria: * dual organ transplantation * rejection within the last three months * history of moderate to severe dementia (defined by dementia severity rating scale ≥19) * history of parkinson's disease * decompensated liver disease * active cancer * uncontrolled depression or anxiety * blindness * deafness * intellectual disabilities * pregnancy * egfr \<15 ml/min/1.73 m2 at the time of enrollment * total bilirubin \>3.0 mg/dl

Keywords: neurocognitive function tacrolimus kidney transplant recipients tremor insomnia
spinal and supra-spinal pain mechanisms in patients with fibromyalgia

Conditions: Fibromyalgia; Pain

Summary: fibromyalgia (fm) patients have increased windup (wu). however, wu of fm patients is only quantitatively but not qualitatively different from healthy controls (hc). thus wu abnormalities of fm patients could be the result of supra-spinal and not the result of spinal pain mechanisms. the study team will test this hypothesis by sensitizing fm patients with topical capsaicin.

the study team hypothesizes that at baseline the slopes of sensitivity adjusted wu of fm patients are not statistically different from hc. however, after capsaicin application, the slopes of sensitivity adjusted wu will be significantly different from baseline and greater than those of hc, suggesting central sensitization. this would imply that fm patients are sensitive to heat pain but not sensitized.

Eligibility criteria:
inclusion criteria: * individuals diagnosed with fibromyalgia will have pain of duration \> 6 months and meeting the 1990 research diagnostic criteria for fm (acr). * healthy, pain-free age matched controls without chronic pain exclusion criteria: * allergy to red chili peppers; * pregnant; * significant hearing loss; * presence of chronic disease (e.g. cancer, cardiovascular disease, liver disease, kidney disease, diabetes, etc.). * fm patients must be willing to discontinue or hold their fm related medications for at least 5 half-lives.
retrospective cohort study of intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: the investigators design a retrospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification，cost-effective, treatments and prognosis of chinese hospitalized adult patients with intracerebral hemorrhage.

intracerebral hemorrhage (ich) remains a devastating disease with high mortality, yet few therapeutic managements have been proved effective. large quantities of work needs to be done to fully delineate the prevalence and prognosis of ich. hence, the investigators design a prospective, observational cohort study to provide contemporary information on the prevalence, characteristics, risk stratification，cost-effective, treatments and prognosis of chinese hospitalised adult patients with ich.

Eligibility criteria:
inclusion criteria: * hospitalized patients over 18 years old of primary intracerebral hemorrhage. exclusion criteria: 1. patients of secondary intracerebral hemorrhage，such as hemorrhagic transformation of ischemic stroke, aneurysmal, cavernomas, arterio- venous malformations, central venous thrombosis, trauma-related, or tumor 2. isolated intraventricular hemorrhage or subarachnoid hemorrhage pregnant patients 3. unavailability to get complete blood cell samples and presenting contraindications or refusal to mri 4. patients cannot be followed up for any reasons. 5. patients death in 24 hours 6. pregnant patients 7. surgical evacuation of hematoma

Keywords: primary intracerebral hemorrhage hypertension perihematomal edema secondary brain injury remote diffusion-weighted imaging lesions(r-dwils) immune response multimodel image cohort mri
pain after laparoscopic cholecystectomy with bilateral tranversus abdominis plane (tap) block versus local anesthetic infiltration

Conditions: Postoperative Pain

Summary: the purpose if to find out if analgesia with bilateral ultrasound-guided tranversus abdominis plane (tap) block with ropivacaine 0.5% is better than analgesia with local infiltration of trochar sites with ropivacaine 0.5% in patients undergoing laparoscopic cholecystectomy. our hypothesis is that in laparoscopic cholecystectomy, bilateral tap blocks will reduce postoperative pain scores when compared to conventional postoperative pain control with local infiltration of trochar insertion sites.

the purpose if to find out if analgesia with bilateral ultrasound-guided tranversus abdominis plane (tap) block with ropivacaine 0.5% is better than analgesia with local infiltration of trochar sites with ropivacaine 0.5% in patients undergoing laparoscopic cholecystectomy. our hypothesis is that in laparoscopic cholecystectomy, bilateral tap blocks will reduce postoperative pain scores when compared to conventional postoperative pain control with local infiltration of trochar insertion sites.

Eligibility criteria:
inclusion criteria: 1. patient ages 18-64 2. american society of anesthesiology physical status i, ii or iii 3. inpatients scheduled to undergo laparoscopic cholecystectomy at ben taub general hospital exclusion criteria: 1. open cholecystectomy - excluded due to increased levels of pain in open procedures 2. scheduled for ambulatory surgery 3. renal dysfunction (serum cr \> 1.2) - excluded due to potential altered metabolism of anesthetic and pain medications 4. coagulopathy or anticoagulation - increased risk of bleeding from nerve block injection 5. allergy or contraindication to any of the study medications or anesthetic agents 6. chronic opioid analgesic use at home - excluded due to potential difficulty in assessing pain caused by the procedure alone 7. patient inability to properly describe postoperative pain to investigators (language barrier, dementia, delirium, psychiatric disorder) 8. pregnancy 9. prisoners 10. patient or surgeon refusal
effects of antirheumatic treatment on levels of survivin in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: to validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.

in a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. no intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. the study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. the patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.

Eligibility criteria:
inclusion criteria: * patients fulfilling the ra classification criteria according to the acr/eular exclusion criteria: * patients at stable/unchanged anti-rheumatic treatment * other serious physical or mental illness * lack of knowledge in swedish making answering the questionnaires impossible

Keywords: survivin biomarker of pharmacological response antirheumatic treatment methotrexate sulfasalazin abatacept tocilizumab tofacitinib/baricitinib
rhythmic reading training compared to 'abilmente' method

Conditions: Developmental Dyslexia

Summary: the purpose of the present study is to compare the effectiveness of rhythmic reading training (rrt), a computer-assisted intervention method that combines sublexical reading exercises with rhythm processing, and that of a multimodal intervention comprising different methodology, called 'abilmente'. all interventions were delivered for a period ranging 1-2,5 months, in 60 minutes biweekly sessions.


Eligibility criteria:
inclusion criteria: * having been diagnosed with dd (icd-10 code: f81.0) on the basis of standard inclusion and exclusion criteria (icd-10: world health organization, 1992) and of the diagnosis procedure followed in the italian practice exclusion criteria: * presence of comorbidity with other neuropsychiatric or psychopathological conditions (whereas comorbidity with other learning disabilities were allowed) * exclusion criteria for the use of tdcs (e.g. epilepsy, pregnancy).

Keywords: reading developmental dyslexia music rhythm intervention
interventions on non-prescription dispensing of antibiotics in community pharmacies

Conditions: Non-Prescription Drug Misuse; Acute Respiratory Tract Infection

Summary: this study was a randomized controlled trial conducted in community pharmacies. empirical data were collected primarily using standardized patient methods. in hubei province, 400 community pharmacies were randomly selected and assigned to the intervention group and the control group according to the ratio of 1:1. a one-month intervention was conducted in community pharmacies in the intervention group, which included both social surveillance and health education. first, on-site training was provided to community pharmacy staff. respiratory physicians and pediatricians were invited to give health education lectures on disease diagnosis and treatment, medication use, etc. second, signs were posted or hung in the community pharmacies of the intervention group, saying that "antibiotics need to be purchased with a prescription, and you are welcome to call the 12315 hotline to report if you find any sales without a prescription", in order to open up the channels of social supervision and to form a social surveillance intervention. the control group only received the regular drug supervision and management measures in hubei province. the primary outcome is to observe the proportion of community pharmacies selling antibiotics without a prescription.


Eligibility criteria:
inclusion criteria: * the qualification of retail pharmacies to sell antimicrobial drugs complies with relevant regulations and requirements, ensuring that the study participants operate legally within the regulatory framework. * pharmacies located in hubei province. exclusion criteria: * the retail pharmacy plans to undergo major changes during the study period, such as relocation, renovation, shutdown, or closure; * retail pharmacies that refused to respond to the call for training from the hubei provincial drug administration; * participants had poor compliance and do not participate in the intervention as required by the trial on multiple occasions; * subjects withdrew from the study on their own or were lost to follow-up.

Keywords: antibiotic community pharmacy non-prescription randomized controlled trial
clinical trial of vagus nerve stimulation for treatment of refractory epilepsy

Conditions: Refractory Epilepsy

Summary: evaluate the long-term clinical effectiveness and safety of the pins vagus nerve stimulator to patients with refractory epilepsy.


Eligibility criteria:
inclusion criteria: 1. age 6-60. 2. having tried at least two appropriate anti-epileptic drugs (aeds) tested to tolerance or to blood levels at upper end of the target range of which at least 2 have been tolerated at normal dose. 3. at least 1 seizure per month. 4. in good health except epilepsy. 5. with normal mmse score 6. patients or his(her) familyscould understand this method and sign the informed consent 7）patients with good compliance and could complete postoperative follow-up. exclusion criteria: 1. results of mri remind epilepsy caused by intracranial space-occupying lesions. 2. the vagus nerve lesion and damage 3. tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental disease，pepticulcer，diabetes type 1，bad health etc, and other surgical contraindication 4. alcohol addiction, smoking, and sleep-related breathing disorders

Keywords: pins vns refractory epilepsy
study of dr. pyke's supplement for stream (s4s) in men with prostatism and ed

Conditions: Prostatism; Erectile Dysfunction

Summary: this is the first clinical trial of dr. pyke's supplement for stream (s4s), a proprietary combination of panax ginseng extract, l-citrulline, beta-sitosterol and vitamin d3, to investigate its effects on prostatism and erections, and its tolerability, when taken daily and twice-daily for 2 weeks.

this is a 2-week clinical trial of dr. pyke's supplement for stream (s4s), a proprietary combination of panax ginseng extract, l-citrullline, beta-sitosterol and vitamin d3, investigating its lower urinary tract effects, sexual effects, and tolerability in two dose regimens-daily for a week and twice daily for a week--in men who have lower urinary tract symptoms (luts) and may have erectile dysfunction (ed). no clinic visits are required. subjects will be consented, screened, supplied with s4s, and tested via the internet. subset analyses will evaluate effects in three populations: men with at least moderate lower urinary tract symptoms (luts), according to standard score cutoff; men with at least moderate erectile dysfunction (ed, according to standard score cutoff; and all men dissatisfied with their urinary function and meeting minimal criteria for inclusion.

Eligibility criteria:
inclusion criteria: inclusion requirements for all subjects 1. men at least 40 years of age 2. screening ipss qol must be 4-6: if you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that? delighted (0), pleased (1), mostly satisfied (2), mixed (3), mostly dissatisfied (4), unhappy (5), terrible (6) 3. gives informed consent for study and is willing to take the treatments and complete the scheduled evaluations 4. willing to buy s4s for $30, with the understanding that a rebate of $30 or a coupon for $30 off the cost of a second 30-dose supply of s4s will be offered if the subject completes the electronic questionnaires at the end of the treatment required for target efficacy subset meets criterion for at least moderate ed: iief-5 (erectile function) score \<13 - or: meets criterion for at least moderate lower urinary tract symptoms (luts): ipss score at least 20 exclusion criteria: 1. known allergy or sensitivity to ginseng, l-citrulline, canola oil or soybean oil. 2. current severe side effects from any drug 3. using medication(s) for angina pectoris, luts, or ed and has not consulted personal physician on advisability of participating in this study. 4. women

Keywords: benign prostatic hypertrophy erectile dysfunction nutritional supplements prostatism lower urinary tract symptoms, male
adenosine vs af termination for paroxysmal af ablation

Conditions: Paroxysmal Atrial Fibrillation

Summary: this study investigates impact of adenosine versus af inducibility and subsequent termination on the acute and long-term outcome of paroxysmal af ablation.

despite intensive efforts to increase single procedure success rates of pulmonary vein isolation (pvi) for paroxysmal atrial fibrillation (af), an arrhythmia-free surveillance has not raised beyond 80%. this prospective, randomized study investigates the efficacy of two different procedural endpoints in terms of single-procedure arrhythmia-free outcome. a total number of 152 patients undergoing de-novo catheter ablation for paroxysmal af will be randomized to two different treatment arms. in group-a patients, pvi will be performed with the patient either in spontaneous or induced af. if af will not terminate with pvi, ablation will be continued by targeting extra-pv af sources with the desired endpoint of termination to sinus rhythm (sr). the ablation procedure in group-b patients consists of pvi exclusively, regardless to the underlying rhythm. in this group, all isolated pvs will be challenged to adenosine administration in the attempt to reveal and ablate dormant conduction. the primary endpoint is arrhythmia-free survival during a follow-up of 1 year.

Eligibility criteria:
inclusion criteria: * patients with paroxysmal af * de-novo af ablation * age \> 18 years exclusion criteria: * persistent af * previous cardioversion

Keywords: paroxysmal atrial fibrillation pulmonary vein isolation adenosine af terminatin